[go: up one dir, main page]

EA201890741A1 - Биспецифические антитела против cgrp/il-23 и их применения - Google Patents

Биспецифические антитела против cgrp/il-23 и их применения

Info

Publication number
EA201890741A1
EA201890741A1 EA201890741A EA201890741A EA201890741A1 EA 201890741 A1 EA201890741 A1 EA 201890741A1 EA 201890741 A EA201890741 A EA 201890741A EA 201890741 A EA201890741 A EA 201890741A EA 201890741 A1 EA201890741 A1 EA 201890741A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bispecific antibodies
cgrp
applications
antibodies against
against cgrp
Prior art date
Application number
EA201890741A
Other languages
English (en)
Inventor
Роберт Ян Беншоп
Барретт Аллан
Рон Ли Дж. Милликан
Кейтрин Бротигем Бейдлер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201890741A1 publication Critical patent/EA201890741A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены биспецифические антитела, которые связывают кальцитонин-ген-связанный пептид (CGRP) и интерлейкин-23 (IL-23), и характеризуются как обладающие высокой аффинностью и сильными одновременными нейтрализующими свойствами как для CGRP, так и для IL-23. Биспецифические антитела по изобретению полезны для лечения различных аутоиммунных заболеваний, включая воспалительные заболевания кишечника, такие как болезнь Крона и язвенный колит, псориатический артрит (PsA) и анкилозирующий спондилоартрит (AS).
EA201890741A 2015-10-30 2015-10-30 Биспецифические антитела против cgrp/il-23 и их применения EA201890741A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/058362 WO2017074428A1 (en) 2015-10-30 2015-10-30 Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201890741A1 true EA201890741A1 (ru) 2018-10-31

Family

ID=54477401

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890741A EA201890741A1 (ru) 2015-10-30 2015-10-30 Биспецифические антитела против cgrp/il-23 и их применения

Country Status (12)

Country Link
US (1) US20180291093A1 (ru)
EP (1) EP3368066A1 (ru)
JP (1) JP6592600B2 (ru)
KR (1) KR20180054851A (ru)
CN (1) CN108135983A (ru)
AU (1) AU2015413277A1 (ru)
BR (1) BR112018007214A2 (ru)
CA (1) CA3003243A1 (ru)
EA (1) EA201890741A1 (ru)
IL (1) IL258534A (ru)
MX (1) MX2018005135A (ru)
WO (1) WO2017074428A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200146269A1 (en) * 2018-11-09 2020-05-14 The Broad Institute, Inc. Methods and compositions for modulating innate lymphoid cell pathogenic effectors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597915A (en) * 2007-02-28 2013-08-30 Merck Sharp & Dohme Combination therapy for treatment of immune disorders
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
EP2604279A1 (en) * 2008-03-27 2013-06-19 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
KR20150080033A (ko) * 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
CN108359008B (zh) * 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23

Also Published As

Publication number Publication date
CN108135983A (zh) 2018-06-08
CA3003243A1 (en) 2017-05-04
IL258534A (en) 2018-06-28
AU2015413277A1 (en) 2018-04-12
MX2018005135A (es) 2018-06-06
JP6592600B2 (ja) 2019-10-16
BR112018007214A2 (pt) 2018-10-16
JP2019501114A (ja) 2019-01-17
KR20180054851A (ko) 2018-05-24
EP3368066A1 (en) 2018-09-05
US20180291093A1 (en) 2018-10-11
WO2017074428A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
SA522431756B1 (ar) Tigit أجسام مضادة لـ
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
EA201790465A1 (ru) Антитела, композиции и применение
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PE20190737A1 (es) Anticuerpos anti-cd27
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
TN2016000042A1 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
TN2015000348A1 (en) Antibodies that bind il-23
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
EA201791734A1 (ru) Способ лечения воспалительных заболеваний
WO2015187521A3 (en) Anti-blys antibodies
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA201890741A1 (ru) Биспецифические антитела против cgrp/il-23 и их применения
MX2018009218A (es) Anticuerpos de cgrp y sus usos.